Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo.
about
Contemporary and emerging strategies for eliminating human African trypanosomiasis due to Trypanosoma brucei gambiense: reviewPersistent digestive disorders in the tropics: causative infectious pathogens and reference diagnostic testsShould I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of CongoPredicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of CongoHuman African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency?A CATT negative result after treatment for human African trypanosomiasis is no indication for cure.Quantifying the burden of rhodesiense sleeping sickness in Urambo District, TanzaniaDiagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasisHuman african trypanosomiasis diagnosis in first-line health services of endemic countries, a systematic review.A mixed methods study of a health worker training intervention to increase syndromic referral for gambiense human African trypanosomiasis in South Sudan.From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study.Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan.Treatment options for second-stage gambiense human African trypanosomiasis.[Human African trypanosomiasis in Côte d'Ivoire and Burkina Faso: optimization of epidemiologic surveillance strategies].Human African trypanosomiasis in a rural community, Democratic Republic of Congo.Social stigma towards neglected tropical diseases: a systematic review.Health care-seeking behaviour and diagnostic delays for Human African Trypanosomiasis in the Democratic Republic of the Congo.Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.The socio-economic burden of human African trypanosomiasis and the coping strategies of households in the South Western Kenya foci.The impact of passive case detection on the transmission dynamics of gambiense Human African Trypanosomiasis.Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasisIntegrating innovations: a qualitative analysis of referral non-completion among rapid diagnostic test-positive patients in Uganda's human African trypanosomiasis elimination programmeEthical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for
P2860
Q26825682-9D48EB13-D09C-47A5-83AA-085C1A1F7E81Q27004352-00D56727-8246-4BC4-AAF9-CE79B2C48CC5Q28478935-9CBEE2A8-5AAD-4369-AAE9-E16D7036F82BQ28555206-71CA3C52-70E3-4CB3-89F1-A04E192A8316Q29056943-9003EB4C-2BC5-4379-AC00-76727CCA8DE8Q33528943-F56641D1-225E-422A-9595-EA588C1CC6F6Q33745212-42D26216-D6EF-4988-9BE8-D7D5C180CCB8Q33834052-107E3791-CF53-4B5C-8FC3-877ABC0ED8B1Q34305891-2ABA6917-C640-43DD-A4FF-EE164E60C7E4Q34500882-1A4593A7-CEFB-4CCD-8E96-67F8FF9272FFQ35126629-678649D4-834B-49E7-8117-4B1B8BEFA130Q35345427-957FE962-990F-459B-B344-9B8483FC03F9Q36198356-36DB68A9-9C0B-4DAA-A615-BF19B539B4D9Q36551049-31B59772-B8F4-4BBC-B54C-3D7ACF0DA0EEQ37034565-2184FB92-F620-40BB-B53C-B99B0B520278Q37302722-B4C05A4D-750E-4EBF-ACAC-C84463239CAEQ38759672-4D240847-A88D-4489-9391-91C2B38D05BFQ39052722-94CA9873-CB09-4915-964B-5C69B4525D76Q39401301-62DF2BD0-E0CA-4190-A87E-27F647259D9FQ47186581-D856E7B7-EB78-4908-9C88-6E73D7815356Q52602671-4E595616-3751-4EE5-B0D1-2C3FCE41C82AQ56504613-C985EAC1-81EA-44D9-BD72-0C6FE274F7D3Q56888277-5D63E30E-7DD8-439E-B390-CAD1B12F9DC2Q58842233-64092DE3-B33B-4C79-B532-E7DD182A7135
P2860
Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@en
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@nl
type
label
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@en
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@nl
prefLabel
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@en
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@nl
P2093
P1476
Drug toxicity and cost as barr ...... Democratic Republic of Congo.
@en
P2093
P Van der Stuyft
V Kande Betu Ku Mesu
P2860
P304
P356
10.1111/J.1365-3156.2006.01768.X
P577
2007-02-01T00:00:00Z